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NK cells are innate lymphoid cells that mediate potent
anti-tumor responses against B cell malignancies in con-
junction with anti-CD20 mAbs. ALT-803 is a superago-
nist IL-15 and dimeric IL-15Ra-IgG-Fc fusion protein
that effectively trans-presents IL-15 and exhibits pro-
longed in vivo pharmacokinetics compared to rhIL-15.
We hypothesized that ALT-803 will augment anti-CD20
mAb (rituximab)-directed NK cell ADCC against B cell
lymphomas, facilitating NK cell-mediated lymphoma
clearance. Short-term in vitro activation with ALT-803
(0.35-35 ng/mL) increased the expression of the cytotoxic
effector protein granzyme B (p < 0.05) in human NK
cells. ALT-803 also potentiated rituximab-directed NK
cell ADCC against Raji (27% vs. 74%, E:T 25:1, p < 0.01)
and Daudi (39% vs. 84%, E:T 2:1, p < 0.05) human B cell
lymphoma lines. Moreover, activation of NK cells with
ALT-803 significantly augmented CD20-specific ADCC
against primary human follicular lymphoma cells in vitro
(Figure 1, 11% vs. 33% at a 2.5:1 E:T ratio, p < 0.001).
Animal models were employed to assess ALT-803 modu-
lation of NK cell-mediated ADCC against B cell lym-
phoma in vivo. First, Daudi cells were engrafted into NK
cell-competent SCID mice. Groups were treated with
vehicle (day 15,18), rituximab (day 15,18), ALT-803 (day
15,18), or rituximab+ALT-803, and assessed for Daudi
cell percentages in the BM at day 22. Mice treated with
rituximab+ALT-803 combination therapy had signifi-
cantly reduced Daudi cell burden in BM, compared to
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Figure 1 ALT-803 enhances NK cell ADCC against primary follicular lymphoma. (A) Representative 4 hour flow-based ADCC assay
demonstrating killing of CD19+ lymphoma cells at the indicated effector target ratios after 24 hours of stimulation with 35 ng/ml ALT-803 and
30 minute FL cell labeling with rituximab or control IgG1 monoclonal antibody. Effectors were purified (>95% CD56+CD3-) NK cells. (B) Summary
data (N = 5 lymphoma sample targets, N = 15 normal NK cell donors, N = 5 independent experiments) showing the dose-dependent increase
in mean ADCC enhanced by ALT-803. *p < 0.001
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rituximab, ALT-803, or vehicle treatment (vehicle vs.
ALT-803+rituximab, 38 ± 7% vs. 5 ± 8%, P = 0.005). The
enhanced antitumor activity of the combination therapy
was ALT-803 dose-dependent (p < 0.02 for 0.02-0.2 mg/
kg ALT-803 + rituximab compared to rituximab alone).
Furthermore, mice treated with ALT-803+rituximab had
superior survival compared to ALT-803 or rituximab
monotherapy (Figure 2, P < 0.05). In the second model,
Raji B cells expressing luciferase were engrafted into
immunodeficient NOD-SCID-gc
-/- mice (day 0), and trea-
ted with primary human NK cells (day 3) plus vehicle,
ALT-803 (0.05 mg/kg q3-4 days), rituximab (day 3), or
ALT-803+rituximab. At day 16, ALT-803+rituximab
exhibited a significant reduction in Raji signal compared
to the control groups (p < 0.05). ALT-803 was well toler-
ated at all of the administered dose levels in combination
with rituximab. Thus, ALT-803 represents an effective
IL-15 receptor-agonist that augments NK cell cytotoxic
potential and ADCC against malignant B cells in vitro,
and significantly increases rituximab-triggered clearance
of B cell lymphoma by NK cells in two in vivo models.
Based on these findings, a Phase 1/2 clinical trial of ALT-
803 plus rituximab is planned for patients with relapsed/
refractory indolent NHLs.
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Figure 2 Alt-803+rituximab protects against lethal Daudi
lymphoma challenge. Kaplan-Meir survival estimates of SCID mice
injected iv with 1e7 Daudi lymphoma cells (day 0) and treated with
vehicle (PBS). ALT-803 (day 15,18 0.05 mg/kg), rituximab (10 mg/kg
day 15), or ALT-803+rituximab (day 15, 18). N = 7 mice per group.
Significant (p < 0.05) survival improvement with ALT-803+rituximab
compared to vehicle treatment group.
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